RxSight, Inc. (RXST) intrinsic value & 10-year financials
RxSight, Inc. (RXST) has a Graham intrinsic value of $2.49 per share. At $4.51 on Oct 17, 2026, the stock trades 81% above that value. Over the last 7 fiscal years revenue grew 55.7% a year to $134.5M, with an average return on invested capital of -11.3%.
- Graham intrinsic value
- $2.49
- Share price (Oct 17, 2026)
- $4.51
- Price vs Graham value
- 81% above
- Market cap
- $184.2M
- Revenue (FY2025)
- $134.5M
- Revenue growth (7-yr CAGR)
- 55.7%
- ROIC (10-yr avg)
- -11.3%
- Free cash flow (FY2025)
- -$19.3M
RXST 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $134.5M | -$38.9M | -$0.95 | -$19.3M | -35.8% | -17.8% |
| FY2024 | $139.9M | -$27.5M | -$0.71 | -$22.4M | -26.3% | -17.2% |
| FY2023 | $89.1M | -$48.6M | -$1.41 | -$46.4M | -56.2% | -36.7% |
| FY2022 | $49.0M | -$66.8M | -$2.41 | -$61.2M | -129.2% | -45.5% |
| FY2021 | $22.6M | -$48.7M | -$1.78 | -$46.6M | -233.6% | 40.9% |
| FY2020 | $14.7M | $27.6M | $0.07 | -$37.7M | -241.3% | 8.5% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
RxSight, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
RxSight, Inc. has historically struggled to out-earn its cost of capital, averaging just -11.3% ROIC.
RxSight, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, RxSight, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $2.49 per share.